Companies ›Healthcare ›CGEN.O

CGEN.O — NASDAQ Biotechnology & Life-Science Tools

Compugen Ltd

$2,38

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

—

P/E

—

EV / Rev

—

Div yield

—

Op margin

43,1 %

ROE

34,4 %

Net margin

48,6 %

Debt / equity

0,00

Beta

—

52w range

—

Volume

483

Day range

$2,65–$2,73

Prev close

$2,65

Open

$2,72

Next earnings

—

Ex-dividend

—

TR 1Y

—

About

Compugen maintains a strong liquidity position, with $90.6 million in cash and equivalents, representing 57.9% of total assets. The company has no long-term debt, and its debt-to-equity ratio is 0.0, indicating a conservative capital structure. The current ratio of 6.56 suggests a robust ability to meet short-term obligations. Profitability metrics are strong, with a return on equity (ROE) of 34.4% and a return on assets (ROA) of 22.6%. These figures exceed the typical thresholds for biotechnology firms, which often prioritize R&D over immediate profitability. Gross profit margin is 87.3%, and operating margin is 43.0%, both of which are in line with industry norms for early-stage biotech companies. Geographically, Compugen's revenue is not disclosed by region in the latest financials, but the company is headquartered in Israel and operates globally. The firm's revenue is primarily derived from licensing and collaboration agreements, with no single customer accounting for more than 10% of total revenue. Growth in the current fiscal year is expected to be modest, with no significant revenue increase projected. The company's focus remains on advancing its pipeline through partners

Business. Compugen Ltd (CGEN.O) is a biotechnology and medical research company engaged in healthcare diagnostics. The firm is headquartered in Israel and primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.

Classification99 %

SectorHealth Care

Industry groupBiotechnology & Life-Science Tools

Generated · model-assisted

Sell-side consensus

—consensus pending

— buy— hold— sell

Avg 12m price target—

Upcoming events

— missing data

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts

—

not yet wired

Ownership→

Northern Trust Investments, Inc.

largest disclosed fund holder

Profitability→

34,4 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning CGEN.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to CGEN.O. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Compugen Ltd (CGEN.O) is a biotechnology and medical research company engaged in healthcare diagnostics. The firm is headquartered in Israel and primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.

Classification99 %

SectorHealth Care

Industry groupBiotechnology & Life-Science Tools

AI synthesis

GENERATED

Profitability metrics are strong, with a return on equity (ROE) of 34.4% and a return on assets (ROA) of 22.6%. These figures exceed the typical thresholds for biotechnology firms, which often prioritize R&D over immediate profitability. Gross profit margin is 87.3%, and operating margin is 43.0%, both of which are in line with industry norms for early-stage biotech companies.

Geographically, Compugen's revenue is not disclosed by region in the latest financials, but the company is headquartered in Israel and operates globally. The firm's revenue is primarily derived from licensing and collaboration agreements, with no single customer accounting for more than 10% of total revenue.

Growth in the current fiscal year is expected to be modest, with no significant revenue increase projected. The company's focus remains on advancing its pipeline through partnerships rather than direct commercialization. Looking ahead, the next fiscal year is expected to show similar trends, with the company likely to remain in the R&D phase for most of its programs.

Risk factors are limited, with no immediate liquidity or dilution concerns. The company has no long-term debt and a low dilution risk, as shares outstanding for both basic and diluted are identical. No recent equity issuance or ATM programs have been disclosed, and there are no dilution-related flags in the latest filings.

Recent events include the continued development of its immuno-oncology pipeline, with several programs in preclinical and clinical stages. The company has also entered into new licensing agreements, which are expected to provide future revenue streams. No material adverse events were disclosed in the latest 10-K filing.

Key takeaways

Compugen has a strong liquidity position with no long-term debt and a current ratio of 6.56.
The company's ROE of 34.4% and ROA of 22.6% indicate strong profitability for a biotech firm.
Revenue is diversified across multiple licensing and collaboration agreements, with no single customer dependency.
Growth is expected to remain modest in the near term, with a focus on R&D and pipeline development.
The company presents low liquidity and dilution risk, with no recent equity issuance or ATM activity.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Valuation

Market price

$2,38

Market cap

—

Enterprise valueⓘ

—

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

$102.7M

Net cashⓘ

$90.6M

Current ratioⓘ

6.6

Debt / equityⓘ

0.0

ROAⓘ

22.6%

ROEⓘ

34.4%

Cash conversionⓘ

90.0%

CapEx / revenueⓘ

-0.4%

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

Peer comparison8 peers · vs CGEN · multiples and returns

IQV—

Iqvia Holdings Inc

$181,94

30,9B USD

P/E

22,7x

— vs self

Div yield

—

— vs self

ROE

21,9 %

-12,5 vs self

CRL—

Charles River Laboratories

$230,87

11,4B USD

P/E

—

— vs self

Div yield

—

— vs self

ROE

-4,6 %

-39,0 vs self

MEDP—

Medpace Holdings Inc

$576,00

16,7B USD

P/E

34,4x

— vs self

Div yield

—

— vs self

ROE

75,4 %

+41,0 vs self

ALKS—

Alkermes PLC

$49,53

8,2B USD

P/E

39,8x

— vs self

Div yield

—

— vs self

ROE

8,4 %

-26,0 vs self

PIII—

P3 Health Partners Inc

$10,20

73,8M USD

P/E

—

— vs self

Div yield

—

— vs self

ROE

95,3 %

+60,9 vs self

ORGO—

Organogenesis Holdings Inc

$2,38

306,2M USD

P/E

9,0x

— vs self

Div yield

—

— vs self

ROE

8,5 %

-25,9 vs self

NAGE—

Niagen Bioscience Inc

$3,53

281,1M USD

P/E

17,4x

— vs self

Div yield

—

— vs self

ROE

22,7 %

-11,7 vs self

SPRY—

Ars Pharmaceuticals Inc

$5,51

547,1M USD

P/E

—

— vs self

Div yield

—

— vs self

ROE

-149,9 %

-184,3 vs self

Market position

Stress test

— missing data

Predictor forecast

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Consensus distribution

sell-side coverage

Recommendation distribution6 analysts

Strong buy3

Buy3

Hold0

Sell0

Strong sell0

12-month price target$6,20 · Median $4,00

Low $4,00High $13,00

Operating income · consensus-24,7M USD

EPS surprise

+252,0 %

reported vs consensus · beat

Revenue surprise

+294,1 %

reported vs consensus · beat

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

Low$4,00

Mean$6,20

Median$4,00

High$13,00

Spot$2,38

+160.5 %implied to mean12-month sell-side price targets · ▲ spot

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskLow

Filing-based flags

No immediate filing-based liquidity or dilution flags were detected.

Benchmarks vs cohort

Op Margin43,0 %Above P75

Net Margin48,6 %Above P75

ROE34,4 %Above P75

Capex / Rev-0,4 %Above median

D/E0,00Above median

Cash Conv0,90Below median

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

Derivative transactions

Net disposed 46 000 sh13 exercises2 insiders

Ophir EranDirector, President and CEO · Share Option (right to buy) → Ordinary SharesDisposed 5 000 @ $0,83exercise · 2026-04-24
Levine ZuritSVP, Business Development · Share Option (right to buy) → Ordinary SharesDisposed 2 000 @ $1,15exercise · 2026-04-24
Ophir EranDirector, President and CEO · Share Option (right to buy) → Ordinary SharesDisposed 5 000 @ $0,83exercise · 2026-04-14
Levine ZuritSVP, Business Development · Share Option (right to buy) → Ordinary SharesDisposed 2 000 @ $1,15exercise · 2026-04-14
Levine ZuritSVP, Business Development · Share Option (right to buy) → Ordinary SharesDisposed 1 125 @ $0,83exercise · 2026-04-10
Levine ZuritSVP, Business Development · Share Option (right to buy) → Ordinary SharesDisposed 2 000 @ $1,15exercise · 2026-04-10
Levine ZuritSVP, Business Development · Share Option (right to buy) → Ordinary SharesDisposed 1 000 @ $1,15exercise · 2026-04-08
Levine ZuritSVP, Business Development · Share Option (right to buy) → Ordinary SharesDisposed 4 375 @ $0,83exercise · 2026-04-08
Levine ZuritSVP, Business Development · Share Option (right to buy) → Ordinary SharesDisposed 2 500 @ $0,83exercise · 2026-04-07
Levine ZuritSVP, Business Development · Share Option (right to buy) → Ordinary SharesDisposed 2 500 @ $0,83exercise · 2026-04-01
Levine ZuritSVP, Business Development · Share Option (right to buy) → Ordinary SharesDisposed 1 000 @ $1,15exercise · 2026-04-01
Ophir EranDirector, President and CEO · Share Option (right to buy) → Ordinary SharesDisposed 5 625 @ $0,83exercise · 2026-04-01
Levine ZuritSVP, Business Development · Share Option (right to buy) → Ordinary SharesDisposed 11 875 @ $0,83exercise · 2026-03-26

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Net Cash
cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
Capex To Revenue
capital_expenditure / revenue
Return On Equity
net_income / total_equity
Debt To Equity
(short_term_debt + long_term_debt) / total_equity
Cash Conversion Ratio
operating_cash_flow / net_income

Source documents

Compugen Ltd Market data — financials · 2026-05-27

Ownership & reference

Top holders

Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$1M
Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$2M
Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$1M
UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$1M
Raymond James & Associates, Inc.Brokerage Firms · as of 2026-03-310,00 %$0M
State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$1M
Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$0M
LPL Financial LLCInvestment Managers · as of 2026-03-310,00 %$0M
Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$0M
PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$0M
JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$0M

Leadership

Anat Cohen-DayagPresident, Chief Executive Officer, Director

Insider activity

Net selling0 buys · 10 sellsnet -$114K2 insiders · last 365d

Levine ZuritSVP, Business Development · Ordinary SharesOther 2 000 @ $1,15$2K · 2026-04-24
Levine ZuritSVP, Business Development · Ordinary SharesSold 2 000 @ $3,20$6K · 2026-04-24
Ophir EranDirector, President and CEO · Ordinary SharesOther 5 000 @ $0,83$4K · 2026-04-24
Ophir EranDirector, President and CEO · Ordinary SharesSold 5 000 @ $3,20$16K · 2026-04-24
Ophir EranDirector, President and CEO · Ordinary SharesOther 5 000 @ $0,83$4K · 2026-04-14
Ophir EranDirector, President and CEO · Ordinary SharesSold 5 000 @ $2,90$15K · 2026-04-14
Levine ZuritSVP, Business Development · Ordinary SharesOther 2 000 @ $1,15$2K · 2026-04-14
Levine ZuritSVP, Business Development · Ordinary SharesSold 2 000 @ $2,80$6K · 2026-04-14
Levine ZuritSVP, Business Development · Ordinary SharesOther 1 125 @ $0,83$933 · 2026-04-10
Levine ZuritSVP, Business Development · Ordinary SharesOther 2 000 @ $1,15$2K · 2026-04-10
Levine ZuritSVP, Business Development · Ordinary SharesSold 3 125 @ $2,56$8K · 2026-04-10
Levine ZuritSVP, Business Development · Ordinary SharesOther 4 375 @ $0,83$4K · 2026-04-08
Levine ZuritSVP, Business Development · Ordinary SharesOther 1 000 @ $1,15$1K · 2026-04-08
Levine ZuritSVP, Business Development · Ordinary SharesSold 5 375 @ $2,42$13K · 2026-04-08
Levine ZuritSVP, Business Development · Ordinary SharesSold 2 500 @ $2,30$6K · 2026-04-07
Levine ZuritSVP, Business Development · Ordinary SharesOther 2 500 @ $0,83$2K · 2026-04-07
Levine ZuritSVP, Business Development · Ordinary SharesOther 1 000 @ $1,15$1K · 2026-04-01
Ophir EranDirector, President and CEO · Ordinary SharesOther 5 625 @ $0,83$5K · 2026-04-01
Ophir EranDirector, President and CEO · Ordinary SharesSold 5 625 @ $2,21$12K · 2026-04-01
Levine ZuritSVP, Business Development · Ordinary SharesSold 3 500 @ $2,20$8K · 2026-04-01
Levine ZuritSVP, Business Development · Ordinary SharesOther 2 500 @ $0,83$2K · 2026-04-01
Levine ZuritSVP, Business Development · Ordinary SharesOther 11 875 @ $0,83$10K · 2026-03-26
Levine ZuritSVP, Business Development · Ordinary SharesSold 11 875 @ $2,04$24K · 2026-03-26

Short positioning

3.0Mshares short+8.2% vs prior

11.17days to cover

69.1%short of daily vol

1.1Kfails-to-deliver

as of 2026-07-15 · short-interest report (free)

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

CGEN.OCanonical

NASDAQ · USD

Intel & risk

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskLow

No immediate filing-based liquidity or dilution flags were detected.

Evidence & claims

From filings & derived data

Net income (YoY) (2025-12-31 vs 2024-12-31): 348.4%Derived (calculated)
Capex (YoY) (2025-12-31 vs 2024-12-31): 159.3%Derived (calculated)
Gross profit (YoY) (2025-12-31 vs 2024-12-31): 218.6%Derived (calculated)
R&D expense (YoY) (2025-12-31 vs 2024-12-31): -8.3%Derived (calculated)
Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): 16.7%Derived (calculated)
Total assets (YoY) (2025-12-31 vs 2024-12-31): 36.2%Derived (calculated)
Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 87.1%Derived (calculated)
Operating income (YoY) (2025-12-31 vs 2024-12-31): 310.4%Derived (calculated)
EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 337.5%Derived (calculated)
Revenue (YoY) (2025-12-31 vs 2024-12-31): 161.1%Derived (calculated)
Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -36.2%Derived (calculated)
Net margin (FY 2025-12-31): 48.6%Derived (calculated)
Gross margin (FY 2025-12-31): 87.3%Derived (calculated)
Return on equity (FY 2025-12-31): 34.4%Derived (calculated)
Return on assets (FY 2025-12-31): 22.6%Derived (calculated)
Current ratio (FY 2025-12-31): 6.56xDerived (calculated)
EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 337.5%Derived (calculated)
Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 397.0%Derived (calculated)
Operating cash flow (annual): USD 31.63MSEC XBRL filing
Cash & equivalents (annual): USD 90.6MSEC XBRL filing
Shareholders' equity (annual): USD 102.73MSEC XBRL filing
Operating income (annual): USD 31.33MSEC XBRL filing
Revenue (annual): USD 72.76MSEC XBRL filing
EPS (basic) (annual): USD-PER-SHARES 0SEC XBRL filing

Showing 24 of 60 surfaced claims.

Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

The Thread

Everything we know, in order

2026-08-03 00:00 UTCTRANSCRIPTEarnings call — Q3 2026

2026-06-20 12:34 UTCANALYSTAnalyst coverage initiated

2026-05-18FILINGZK2635352 →

2026-04-24 00:00 UTCINSIDER33 insider transactions — 2026-04 · $120k gross 12 derivative

2026-04-24INSIDERLevine Zurit transacted 2.0k sh Ordinary Shares — SVP, Business Development ~$2k

2026-04-24INSIDERLevine Zurit sold 2.0k sh Ordinary Shares — SVP, Business Development ~$6k

2026-04-24INSIDEROphir Eran transacted 5.0k sh Ordinary Shares — Director, President and CEO ~$4k

2026-04-24INSIDEROphir Eran sold 5.0k sh Ordinary Shares — Director, President and CEO ~$16k

2026-04-24INSIDEROphir Eran disposed of 5.0k sh Share Option (right to buy) — Director, President and CEO

2026-04-24INSIDERLevine Zurit disposed of 2.0k sh Share Option (right to buy) — SVP, Business Development

2026-04-14INSIDEROphir Eran transacted 5.0k sh Ordinary Shares — Director, President and CEO ~$4k

2026-04-14INSIDEROphir Eran sold 5.0k sh Ordinary Shares — Director, President and CEO ~$15k

2026-04-14INSIDERLevine Zurit transacted 2.0k sh Ordinary Shares — SVP, Business Development ~$2k

2026-04-14INSIDERLevine Zurit sold 2.0k sh Ordinary Shares — SVP, Business Development ~$6k

2026-04-14INSIDERLevine Zurit disposed of 2.0k sh Share Option (right to buy) — SVP, Business Development

2026-04-14INSIDEROphir Eran disposed of 5.0k sh Share Option (right to buy) — Director, President and CEO

2026-04-10INSIDERLevine Zurit transacted 1.1k sh Ordinary Shares — SVP, Business Development ~$1k

2026-04-10INSIDERLevine Zurit transacted 2.0k sh Ordinary Shares — SVP, Business Development ~$2k

2026-04-10INSIDERLevine Zurit sold 3.1k sh Ordinary Shares — SVP, Business Development ~$8k

2026-04-10INSIDERLevine Zurit disposed of 1.1k sh Share Option (right to buy) — SVP, Business Development

2026-04-10INSIDERLevine Zurit disposed of 2.0k sh Share Option (right to buy) — SVP, Business Development

2026-04-08INSIDERLevine Zurit transacted 4.4k sh Ordinary Shares — SVP, Business Development ~$4k

2026-04-08INSIDERLevine Zurit transacted 1.0k sh Ordinary Shares — SVP, Business Development ~$1k

2026-04-08INSIDERLevine Zurit sold 5.4k sh Ordinary Shares — SVP, Business Development ~$13k

2026-04-08INSIDERLevine Zurit disposed of 4.4k sh Share Option (right to buy) — SVP, Business Development

2026-04-08INSIDERLevine Zurit disposed of 1.0k sh Share Option (right to buy) — SVP, Business Development

2026-04-07INSIDERLevine Zurit sold 2.5k sh Ordinary Shares — SVP, Business Development ~$6k

2026-04-07INSIDERLevine Zurit transacted 2.5k sh Ordinary Shares — SVP, Business Development ~$2k

2026-04-07INSIDERLevine Zurit disposed of 2.5k sh Share Option (right to buy) — SVP, Business Development

2026-04-01INSIDERLevine Zurit transacted 1.0k sh Ordinary Shares — SVP, Business Development ~$1k

2026-04-01INSIDEROphir Eran transacted 5.6k sh Ordinary Shares — Director, President and CEO ~$5k

2026-04-01INSIDEROphir Eran sold 5.6k sh Ordinary Shares — Director, President and CEO ~$12k

2026-04-01INSIDERLevine Zurit sold 3.5k sh Ordinary Shares — SVP, Business Development ~$8k

2026-04-01INSIDERLevine Zurit transacted 2.5k sh Ordinary Shares — SVP, Business Development ~$2k

2026-04-01INSIDERLevine Zurit disposed of 2.5k sh Share Option (right to buy) — SVP, Business Development

2026-04-01INSIDERLevine Zurit disposed of 1.0k sh Share Option (right to buy) — SVP, Business Development

2026-04-01INSIDEROphir Eran disposed of 5.6k sh Share Option (right to buy) — Director, President and CEO

2026-03-26 00:00 UTCINSIDER3 insider transactions — 2026-03 1 derivative

Showing the 40 most recent of 54 entries.

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Consensus distribution

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Derivative transactions

Actions

Ask Handelsavisen

Ownership & reference

Top holders

Leadership

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread